[Clinical experiences with a new beta-sympatholytic agent Kö 1366 (bunitrolol)].
D000433:1-Propanol / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000605:Amino Alcohols / Q000627:therapeutic use*; D000787:Angina Pectoris / Q000188:drug therapy; D001161:Arteriosclerosis / Q000188:drug therapy; D002082:Butylamines / Q000627:therapeutic use; D005080:Exercise Test; D005260:Female; D006331:Heart Diseases / Q000503:physiopathology; D006801:Humans; D006980:Hyperthyroidism / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy; D009205:Myocarditis / Q000188:drug therapy; D009570:Nitriles / Q000627:therapeutic use; D013614:Tachycardia, Paroxysmal / Q000188:drug therapy
D000319:Adrenergic beta-Antagonists; D000605:Amino Alcohols; D002082:Butylamines; D009570:Nitriles; D000433:1-Propanol
Klinische Erfahrungen mit dem neuen Beta-Sympathikolytikum Kö 1366 (Bunitrolol)